# US 2008/0269281 A1 · Novel Beta-Agonists, Method for Producing Them and Their Use as Drugs

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0269281 A1
- Document ID: US20080269281A1
- Status: Published application
- Kind: A1
- Application number: 12/091,828
- Filed: 2006-10-27
- Published: 2008-10-30
- Earliest claimed: 2005-10-28
- Inventors: Thomas Trieselmann; Rainer Walter; Matthew R. Netherton; Bradford S. Hamilton
- Web page: https://patentgrep.com/patent/US20080269281A1

## CPC

- C07D 471/04: Ortho-condensed systems
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/08: for glucose homeostasis (pancreatic hormones A61P5/48)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 13/02: of urine or of the urinary tract, e.g. urine acidifiers
- A61P 25/24: Antidepressants
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compounds of the formula which are selective beta-3-agonists and useful for the treatment of obesity and type II diabetes. Exemplary compounds are: ethyl 3-{3-[(R)-2-(3-benzenesulphonylamino-phenyl)-2-hydroxy-ethylamino]-3-methyl-butyl}-3H-imidazo[4,5-b]pyridine-5-carboxylate and 3-{3-[(R)-2-(3-benzenesulphonylamino-phenyl)-2-hydroxy-ethylamino]-3-methyl-butyl}-3H-imidazo[4,5-b]pyridine-5-carboxylic acid.

## Claims

### Claim at position 1

1: A compound of the formula
wherein
R1 denotes a C1-4-alkyl, thienyl, pyridyl or phenyl group,
wherein the phenyl group may be substituted by one to three fluorine, chlorine or bromine atoms or one to three C1-3-alkyl, C1-3-alkyloxy, trifluoromethoxy or difluoromethoxy groups, wherein the substituents may be identical or different,
R2 denotes a benzimidazolyl group wherein a methyne group in the benzyl moiety is replaced by a nitrogen atom and
which may additionally be substituted by a fluorine, chlorine or bromine atom, a cyano group or a C1-3-alkyl, carboxy, C1-4-alkyloxy-carbonyl or amino group,
and R3 and R4, which may be identical or different, each represent a C1-3-alkyl group, while the alkyl groups contained in the above-mentioned groups may be straight-chain or branched,
or a salt thereof.

### Claim at position 2 (depends on 1)

2: A compound of the formula (I) according to claim 1, wherein
R1 denotes a phenyl group,
R2 denotes a benzimidazol-1-yl group wherein a methyne group in the benzyl moiety is replaced by a nitrogen atom and
which is additionally substituted by a carboxy or C1-4-alkyloxy-carbonyl group,
and R3 and R4 in each case represent a methyl group,
or a tautomer or salt thereof.

### Claim at position 3 (depends on 1)

3: A compound according to claim 1 wherein the compound is the (R)-enantiomer of formula

### Claim at position 4 (depends on 1)

4: A compound according to claim 1 wherein the compound is the (S)-enantiomer of formula

### Claim at position 5 (depends on 1)

5: A compound according to claim 1 selected from the group consisting of:
ethyl 3-{3-[(R)-2-(3-benzenesulphonylamino-phenyl)-2-hydroxy-ethylamino]-3-methyl-butyl}-3H-imidazo[4,5-b]pyridine-5-carboxylate;
3-{3-[(R)-2-(3-benzenesulphonylamino-phenyl)-2-hydroxy-ethylamino]-3-methyl-butyl}-3H-imidazo[4,5-b]pyridine-5-carboxylic acid;
ethyl 1-{3-[2-(3-benzenesulphonylamino-phenyl)-2-hydroxy-ethylamino]-3-methyl-butyl}-1H-imidazo[4,5-c]pyridine-6-carboxylate;
1-{3-[2-(3-benzenesulphonylamino-phenyl)-2-hydroxy-ethylamino]-3-methyl-butyl}-1H-imidazo[4,5-c]pyridine-6-carboxylic acid;
ethyl 1-{3-[2-(3-benzenesulphonylamino-phenyl)-2-hydroxy-ethylamino]-3-methyl-butyl}-1H-imidazo[4,5-b]pyridine-5-carboxylate;
1-{3-[2-(3-benzenesulphonylamino-phenyl)-2-hydroxy-ethylamino]-3-methyl-butyl}-1H-imidazo[4,5-b]pyridine-5-carboxylic acid;
ethyl 3-{3-[(R)-2-(3-benzenesulphonylamino-phenyl)-2-hydroxy-ethylamino]-3-methyl-butyl}-3H-imidazo[4,5-c]pyridine-6-carboxylate; and
3-{3-[2-(3-benzenesulphonylamino-phenyl)-2-hydroxy-ethylamino]-3-methyl-butyl}-3H-imidazo[4,5-c]pyridine-6-carboxylic acid;
or an enantiomer or salt thereof.

### Claim at position 6 (depends on 1, 2, 3, 4, 5)

6: A physiologically acceptable salt of a compound according to claim 1, 2, 3, 4 or 5.

### Claim at position 7

7-10. (canceled)

### Claim at position 8 (depends on 1, 2, 3, 4, 5)

11: A pharmaceutical composition comprising a compound according to claim 1, 2, 3, 4 or 5 or a pharmaceutically acceptable salt thereof and a carrier or excipient.

### Claim at position 9

12-13. (canceled)

### Claim at position 10 (depends on 1, 2, 3, 4, 5)

14: A method for the treatment of obesity or type II diabetes which comprises administering to a host suffering from the same a therapeutically effect amount of a compound according to claim 1, 2, 3, 4 or 5 or a pharmaceutically acceptable salt thereof.
